We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
John H. Stone, MD, MPH
Yoh Zen, MD, PhD, FRCPath
Avinash Kambadakone-Ramesh, MD, DNB, FRCR
J. Matthias Löhr, MD
The Evolving Role of MET TKIs in NSCLC
Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Jyoti Patel, MD
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Treatment Intensification in HR+/HER2- EBC: Who and When?
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education